Journal: Vaccine
Article Title: A phase 1, open-label, randomized study to compare the immunogenicity and safety of different administration routes and doses of virosomal influenza vaccine in elderly.
PMID/MRN: 27667332
Publication Date: 2016-Oct-17
Abstract:
Influenza remains a significant problem in elderly despite widespread vaccination coverage. This randomized, phase-I study in elderly compared different strategies of improving vaccine immunogenicity.
A total of 370 healthy participants (?65years) were randomized equally 1:1:1:1:1:1 to six influenza vaccine treatments (approximately 60-63 participants per treatment arm) at day 1 that consisted of three investigational virosomal vaccine formulations at doses of 7.5, 15, and 45?g HA antigen/strain administered intradermally (ID) by MicronJet600ª microneedle device (NanoPass Technologies) or intramuscularly (IM), and three comparator registered seasonal vaccines; Inflexal Vª (Janssen) and MF59 adjuvanted Fluadª (Novartis) administered IM and Intanzaª (Sanofi Pasteur) administered ID via Soluviaª prefilled microinjection system (BD). Serological evaluations were performed at days 22 and 90 and safety followed-up for 6months.
Intradermal delivery of virosomal vaccine using MicronJet600ª resulted in significantly higher immunogenicity than the equivalent dose of virosomal Inflexal Vª administered intramuscularly across most of the parameters and strains, as well as in some of the readouts and strains as compared with the 45?g dose of virosomal vaccine formulation. Of 370 participants, 300 (81.1%) reported ?1 adverse event (AE); more participants reported solicited local AEs (72.2%) than solicited systemic AEs (12.2%).
Intradermal delivery significantly improved influenza vaccine immunogenicity compared with intramuscular delivery. Triple dose (45?g) virosomal vaccine did not demonstrate any benefit on vaccine's immunogenicity over 15?g commercial presentation. All treatments were generally safe and well-tolerated.
Copyright © 2016 The Authors. Published by Elsevier Ltd.. All rights reserved.